By M. Marin NASDAQ: AEMD READ THE FULL AEMD RESEARCH REPORT Moving to final dosing cohort brings AEMD closer to generating, reporting data to move toward potential regulatory approval Aethlon Medical ...

A clinical trial led by researchers from Hospital Clínic de Barcelona, the August Pi i Sunyer Biomedical Research Institute ...

The study showed that an experimental pill from the company Revolution Medicines almost doubled metastatic pancreatic cancer patients’ survival times compared with chemotherapy.

Sanofi (NASDAQ:SNY) said on Wednesday that it has decided to discontinue the phase 3 MOBILIZE trial evaluating riliprubart in ...

Urteste S.A. (Warsaw Stock Exchange: URT), a company developing innovative technology for the detection of cancer based on urine samples, has enrolled the first patient in the clinical study of the ...

A randomized clinical trial conducted across five countries in 47 pediatric emergency departments, including Ann & Robert H.

The 2026 ASCO annual meeting featured a prostate cancer trials in progress session and a presentation by Dr. Michael Ong discussing TRIPLE-SWITCH (SWOG/CCTG-PR26), a randomized phase III clinical ...

Clinical trials rarely fail overnight, but when recruitment slows, timelines slip and budgets tighten, recovery becomes increasingly complex. This webinar will provide practical, actionable strategies ...

It’s a well-known fact for anyone who has ever tried navigating the world of cancer clinical trials: Finding a research trial that’s a match for you isn’t easy. “It’s a kind of Wild West out there,” ...

Learn about a clinical trial at LSU Health Shreveport that could improve heart function in women with peripartum ...

Real-world studies assess treatment effectiveness and patient experience beyond clinical trial settings, considering broader patient populations. Clinical trials have stricter enrollment criteria, ...

Sign up for CNN’s Wonder Theory science newsletter. Explore the universe with news on fascinating discoveries, scientific advancements and more. The first ...